Best Life Sciences Companies in Taipei, Taiwan
The 144 best Life Sciences companies in Taipei, Taiwan in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: TaiGen Biotechnology.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Taipei
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Bened Biomedical Developer of probiotics for research and development | $10M | — | Series A | — | Frankie Cheng Founder & CEO | WixSentryBootstrap+14 | 54 patents Probiotic lactobacilli therapeutics and diagnostics for metabolic, neurological, and allergic disorders | 1 job opening |
| 2 | 3D Global Biotech Developer of human tissues and organ reconstructed implants | — | — | Public | 28 | — | PHPUIKitLiteSpeed+6 | 323 patents Bio-based agricultural biostimulants and oral care materials from microbial peptide hydrolysates | — |
| 3 | Abnova Proteins and bioreagents for life science research | — | — | Public | 190 | — | — | — | 4 launchs |
| 4 | AcuSolutions Developer of medical imaging devices for intra-operative pathological diagnosis | — | — | Funding Raised | — | Chien Tsai Co-Founder | — | — | — |
| 5 | Advagene Biopharma Developer of immunomodulatory therapies for respiratory diseases and allergies | — | — | Public | 6 | Bryon Chen Founder | PHPBootstraptoastr+10 | 26 patents Intranasal mucosal vaccine formulations and immunomodulatory therapeutics for respiratory diseases | — |
| 6 | Allgenesis Protein therapeutics for disorders in the areas of the CNS and Ophthalmology | — | — | Unfunded | — | Madhu Cherukury Chief Executive Officer | — | — | — |
| 7 | AmCad BioMed Developer of CAD based ultrasound imaging systems | — | — | Public | 34 | — | PHPYouTubeLaravel+9 | 68 patents Patents concentrated in computing, sensing & instrumentation | — |
| 8 | Amed Wound Dressing Hydrogel for wound care application | — | — | Deadpooled | — | Yao-Chien Wang Founder | PHPLaravelApache HTTP Server+7 | 17 patents Antimicrobial wound dressings with controlled release and rapid exudate absorption | — |
Top 12 Life Sciences companies in Taipei
#1
Series A · Taipei, Taipei · founded 2020 · 11 employees$15Mraised▾
Developer of a microscopic system for the identification of proteins and biomarkers. By using proprietary optoproteomics technology it has developed Microscoop that is capable of identifying proteins. It uses automated AI-based recognition algorithms and photochemical labeling reagents, to identify and quantify novel proteins for discovery research and disease mechanism studies.
- Dec 2024Series A$15M
#2
Public · Taipei, Taipei · founded 2013 · 31 employees$38Mraised▾
AP Biosciences is a biotech company that has a therapeutic antibody discovery platform which can be used to generate antibodies against a broad range of target proteins including proteins, peptides, whole cells and haptens. The company's discovery pipeline covers screening/discovery, functionalization, in vitro and in vivo characterization and expression cell line generation. Their platform's central asset is the OmniMab human antibody phage display library which is a broad range, stable, diverse and validated library for the screening of therapeutic antibodies. The company partners with biopharma companies (such as Allgenesis Biotherapeutics, GeneTex, Abnova and CellMax Life) for its discovery programs, and has one IND (bi-specific Ab) and several pre-clinical candidates in its product pipeline.
- Jun 2024Series D$38M
- 2016Grant (prize money)—
- 2015Grant (prize money)—
#3
Series A · Taipei, Taipei · founded 2019$12.5Mraised▾
Developer of precision cancer therapeutics. It offers drug candidates ABT-101 a tyrosine kinase inhibitor targeting HER2 Exon20 insertion from solid tumor cancer, ABT-201 a KRAS inhibitor targeting non-small cell lung cancer, and ABT-301 a small molecule histone deacetylase inhibitor (HDACi).
- Jan 2024Series A$12.5M
#4
Series C · Taipei, Taipei · founded 2015 · 15 employees$51.1Mraised▾
Developer of diagnostics and therapeutics for neurodegenerative disorders. The company focuses on the development of tau, alpha-synuclein, and other proteins that target neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. The company's lead candidate is APNmAb005 a humanized anti-tau antibody specifically targeting human tau aggregates found in tau-related diseases including Alzheimer's Disease.
- Dec 2021Series C$40M
- May 2019Grant (prize money)—
- Jan 2018Series B$11.1M
- Seed—
#5
Series A · Taipei, Taipei · founded 2018 · 20 employees$4Mraised▾
Heroic is a provider of AI-based devices for lung disease diagnosis. The solution offers by the company is used in remote lung sound monitor and in COPD (Chronic Obstructive Pulmonary Disease). The device is also used or the ICU patients as wells as for the COVID-19 patients. The AI-based technology is used to monitor the respiratory rate for the different pathological conditions as respiratory stenosis, obstruction, spasm, pulmonary edema, inflammation, fibrosis, secretion, and infiltration. It also offers an image-based analysis.
- Aug 2023Series A$15.1M
- Mar 2022Series A$500K
- Jul 2020Series A$4M
#6
Series A · Taipei, Taipei · founded 2020$10Mraised▾
Developer of therapeutics for cancer, neurology, and age-related diseases. It offers protein degradation drugs which include AH-001 for the treatment of androgenetic alopecia. It also provides drugs for prostate cancer, lymphoma, pancreatic, and colorectal cancer, neurodegenerative disease, and others.
- Apr 2023Series A$10M
#7
Series A · Taipei, Taipei · founded 2016 · 23 employees$27Mraised▾
Developer of immunotherapy for cancer and immunological diseases. The company's drug candidates include EI-1071 for Alzheimer's disease, tenosynovial giant cell tumors, EI-001 for vitiligo, and others for cancer. The platform has developed the proprietary human single B cell cloning technology and anti-cytokine monoclonal antibodies for targeting the immunosuppressive tumor for cancer treatment.
- Jul 2022Grant (prize money)—
- Aug 2021Series A$27M
- Aug 2020Grant (prize money)$1M
#8
Public · Taipei, Taipei · founded 2001 · 51 employees$99Mraised▾
Developer of therapeutics for infectious diseases and cancer. The company focuses on the discovery, development, and commercialization of therapeutics to treat cancers, infectious diseases and diabetic complications. It markets Nemonoxacin, a drug-resistant anti-infection drug for community-acquired pneumonia. It is developing Burixafor (TG-0054) which is a potent and selective CXCR4 chemokine receptor antagonist.
- Jan 2009Series C$37M
- Nov 2005Grant (prize money)$3.5M
- Mar 2004Series B$38M
- Oct 2003Grant (prize money)$890K
#9
Public · Taipei, Taipei · founded 2011 · 15 employees$32.5Mraised▾
Foresee Pharmaceuticals develops injectables and NCEs for cancer, endocrine disorders, and inflammatory diseases. Its stabilized injectable formulation platform is primarily a controlled release drug delivery platform for small molecules, peptides, and other bioactive. Its lead candidate is in phase III trials for prostate cancer, and another candidate in phase II trials for COPD and asthma. In addition, it has other candidates for acromegaly, opioid dependence, diabetic retinopathy and alport syndrome in preclinical studies. Its pipeline candidates are FP-001 (Leuprolide) for prostate cancer, FP-004 (Buprenorphine) for opioid dependence, and FP-011 (Goserelin) for the breast cancer among others.
- 2020Post IPO—
- Feb 2016Series D$14.5M
- Oct 2014Series C$18M
- 2014Series C—
#10
Acquired · Taipei, Taipei · founded 2014 · 300 employees$20.5Mraised▾
ACT Genomics offers clinical and research services in genomics for cancer. Its clinical offerings include NGS panels for auto-immune disease (ACTImmune), colon cancer (ACTColon), gastric cancer (ACTGastric) and breast cancer (ACTBreast). It also provides pharmacogenomic panels ACTDrug and ACTOnco that help physicians tailor therapies according to the patient's genotype. In addition, the company provides custom genomic services for biopharma companies and research institutions.
- Sep 2020Series B—
- Sep 2018Series B—
- May 2016Series B$12.5M
- Feb 2015Series A$8M
#11
Series B · Taipei, Taipei · founded 2007 · 78 employees$52Mraised▾
TaiMed Biologics is a biotechnology company that develops a monoclonal Antibody (mAb) therapeutics for HIV. The company's lead product, Ibalizumab (TMB-355), won the FDA's breakthrough drug title for HIV. Ibalizumab works by barring the virus' entry into cells by hitting the CD4 receptor, a primary mechanism in the spread of infection. The company recently announced schedule for phase 3 trials for its anti-HIV drug candidate TMB-355.
- 2010Series B$22M
- May 2008Series B$10M
- Sep 2007Series A$20M
#12
Public · Taipei, Taipei · founded 1997 · 112 employees$27.3Mraised▾
TLC Bio is a is a developer of nanomedicines for oncology, ophthalmology, osteoarthritis, and pain management. It uses proprietary lipid-based technologies to develop new formulations (micelles and nanoparticles). It is developing drugs in Oncology, Peripheral Arterial Disease, Ophthalmology, Arthritis, and Anesthetics.
- Oct 2019Post IPO$27.3M
- Jul 2009Post IPO—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Taipei researches in biotechnology
National Taipei University, Taipei Medical University, and Taipei City Hospital lead Taipei's moderately optimistic biotech research, focusing predominantly on cancer metastasis and genetic diversity.
- National Taipei University10
- Taipei Medical University9
- Taipei City Hospital3
- Taipei Municipal YangMing Hospital2
- Taipei Veterans General Hospital2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.